devie medical develops a transcatheter platform for drug delivery to address the unmet medical need in treating bacterial endocarditis. This platform merges advanced medical technology with a proprietary pharmacological concept. The company aims to advance cardiovascular interventions through this novel therapeutic approach.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bacterial endocarditis, an infection of the heart valves, remains a significant challenge in cardiology due to limitations in current treatment options, particularly in cases involving drug-resistant bacteria. Existing therapies often struggle to deliver sufficient drug concentrations directly to the infected tissue, leading to suboptimal outcomes.
Solution
Devie Medical is developing a transcatheter platform designed for targeted drug delivery to treat bacterial endocarditis. The platform aims to improve treatment efficacy by enabling precise and localized delivery of antimicrobial agents directly to the infected heart valve. This approach seeks to overcome the limitations of systemic drug administration and current heart valve therapies, especially in cases where bacteria exhibit drug resistance. By combining advanced medical technology with a proprietary pharmacological concept, Devie Medical intends to enhance the safety and effectiveness of bacterial endocarditis treatment.
Target Audience
The primary target audience includes cardiologists and interventional cardiologists treating patients with bacterial endocarditis, as well as hospitals and medical centers specializing in cardiovascular care.
Features
- Transcatheter-based system for minimally invasive drug delivery
- Targeted delivery to infected heart valve tissue
- Compatibility with various antimicrobial agents
- Potential for improved drug concentration at the site of infection